The UK Cystic Fibrosis Gene Therapy Consortium
Welcome to the UK CFGTC website. Our aim is to develop gene therapy for Cystic Fibrosis (CF).
For more information on Cystic Fibrosis please click here.
Gene Therapy Multi-Dose Clinical Trial Update.
The Consortium are pleased to announce that all the CF patients participating in the Multidose Gene Therapy Trial have now completed administration of their gene therapy or placebo.
Measurements are still being collected from the last few patients, after which the entire patient groups' samples will be analysed.
As the trial is a double-blind study we have no knowledge whatsoever about the outcome at this stage, but once the results have been statistically assessed they will be presented as planned at the North American CF Conference in October.
Wave II Update.
The Wave 2 product (CF gene delivered by a virus) that the Consortium has developed in parallel with Wave 1 over the last decade is now progressing rapidly.
We have chosen the final form of the virus that we will take into CF patients, have learnt how to make the quantities that will be needed for the first clinical trial, and have undertaken preliminary safety studies which have not shown any unexpected problems.
The next stage is to embark on a formal toxicology programme, aiming to be in a first clinical trial in 2017.
Information for Patients on Our Clinical Trial
Consortium Members' Internal Website
Medical Futures Innovation Award 2011